Evaluating “Harmonization” of PD-L1 Assays Using Image Analysis

Back to Resources


  • The current PD-L1/PD-1 checkpoint inhibitor drug and diagnostic landscape is highly complicated, with its complexity set to still increase as new monotherapies and combination therapies are developed.
  • While “PD-L1 harmonization” efforts have demonstrated different immunohistochemistry (IHC) assays to be analytically comparable, the intended use of each assay does not enable these assays to be used interchangeably.
  • Flagship Biosciences’ Computational Tissue Analysis (cTA™) platform leverages digital pathology to enable cross-interpretation of multiple tests, allowing for true harmonization in PD-L1 testing.
  • A comparison of the different tests with cTA™ demonstrates critical attributes of each test that account for the different interpretations applied to each test in its intended-use setting.

Additional Information:

Flagship’s CSO was interviewed by BioCentury to discuss the details and application of the research presented in this poster. Follow the link below to read the full article.


Share this Post: